75,411 resources
By Version
By Authority
By Realm
Start Prev Rows 69000 - 69200 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Auth |
---|---|---|---|---|---|---|---|---|---|
hl7.fhir.uv.ae-research-backport-ig | R4 | ValueSet/adverse-event-supporting-info | AdverseEvent Supporting Information | informative | brr | 2024-04 | uv | hl7 | |
hl7.fhir.uv.ae-research-backport-ig | R4 | ValueSet/adverse-event-participant-function-vs | Adverse Event Participant Functions | informative | brr | 2024-04 | uv | hl7 | |
hl7.terminology | R5 | ValueSet/adverse-event-clinical-research-outcomes | Adverse Event Clinical Research Outcomes | active | 1 | brr | 2023-07 | uv | hl7 |
hl7.fhir.uv.phr | R4 | ValueSet/pcd-sleep-observation-code | Patient contributed data: sleep observation code | informative | pe | 2025-06 | uv | hl7 | |
StandardPatientHealthRecordIG | R4 | ValueSet/pcd-sleep-observation-code | Patient contributed data: sleep observation code | draft | 2023-09 | ||||
hl7.fhir.uv.phr | R4 | ValueSet/pcd-sleep-observation-value | Patient contributed data: sleep stage value | informative | pe | 2025-06 | uv | hl7 | |
StandardPatientHealthRecordIG | R4 | ValueSet/pcd-sleep-observation-value | Patient contributed data: sleep stage value | draft | 2023-09 | ||||
hl7.fhir.us.carin-rtpbc | R4 | ValueSet/rtpbc-prescribable-product-code | RTPBC Prescribable Product Code Value Set | trial-use | 4 | phx | 2020-05 | us | hl7 |
signal.core.r4 | R4 | ValueSet/languages | Common Languages | draft | 5 | fm | 2016-08 | us | hl7 |
ee.hl7.fhir.base.r4 | R4 | ValueSet/eebase-actencountercode | EEBase ActEncounterCode | draft | 2022-09 | hl7 | |||
hl7.terminology | R5 | ValueSet/ex-diagnosisrelatedgroup | Example Diagnosis Related Group Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-diagnosistype | Example Diagnosis Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-diagnosis-on-admission | Example Diagnosis on Admission Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-paymenttype | Example Payment Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-procedure-type | Example Procedure Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-benefitcategory | Benefit Category Codes | active | 1 | fm | 2024-04 | uv | hl7 |
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.3204 | Non-Laboratory Intervention and Procedure | active | 2009-01 | us | |||
hl7.terminology | R5 | ValueSet/claim-subtype | Example Claim SubType Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/consent-action | Consent Action Codes | active | 1 | cbcc | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-action | Contract Action Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-actorrole | Contract Actor Role Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-signer-type | Contract Signer Type Codes | active | fm | 2024-04 | uv | hl7 | |
hl7.terminology | R5 | ValueSet/contract-subtype | Contract Subtype Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-term-subtype | Contract Term Subtype Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-term-type | Contract Term Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/contract-type | Contract Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/coverage-copay-type | Coverage Copay Type Codes | active | 2 | fm | 2024-04 | uv | hl7 |
signal.core.r4 | R4 | ValueSet/coverage-copay-type | Coverage Copay Type Codes | trial-use | 2 | fm | 2019-10 | us | hl7 |
hl7.terminology | R5 | ValueSet/claim-exception | Exception Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/claim-informationcategory | Claim Information Category Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/missing-tooth-reason | Missing Tooth Reason Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/claim-modifiers | Modifier type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/payment-type | Payment Type Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-program-code | Example Program Reason Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/provider-qualification | Example Provider Qualification Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/consent-policy | Consent PolicyRule Codes | active | 2 | cbcc | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/related-claim-relationship | Example Related Claim Relationship Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/ex-revenue-center | Example Revenue Center Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/fundsreserve | Funds Reservation Codes | active | 1 | fm | 2024-04 | uv | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1111.146 | Buprenorphine | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1111.166 | Codeine Schedule II and III | active | 2023-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1111.167 | Alfentanil | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1111.168 | Remifentanil | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1111.169 | Sufentanil | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1125.1 | Schedule IV Benzodiazepines | active | 2025-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.11 | Oxycodone | active | 2023-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.12 | Oxymorphone | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.70 | Morphine | active | 2024-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.71 | Methadone Medications | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.72 | Meperidine | active | 2024-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.73 | Levorphanol | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.74 | Hydromorphone | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.75 | Hydrocodone | active | 2025-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.76 | Fentanyl | active | 2024-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.12 | Butorphanol | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.15 | Opium Combinations | active | 2024-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.16 | Pentazocine | active | 2024-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.17 | Tapentadol | active | 2021-02 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.18 | Tramadol | active | 2024-02 | us | hl7 | ||
hl7.terminology | R5 | ValueSet/adjudication-reason | Adjudication Reason Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/payment-adjustment-reason | Payment Adjustment Reason Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.fhir.us.mihr | R4 | ValueSet/hypertensive-disorders-pregnancy-ICD | ValueSet – Hypertensive Disorders of Pregnancy ICD | draft | 2023-03 | us | hl7 | ||
hl7.fhir.us.mihr | R4 | ValueSet/hypertensive-disorders-pregnancy-SNOMED | ValueSet – Hypertensive Disorders of Pregnancy SNOMED CT | draft | 2023-03 | us | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-specialty | Swissnoso Specialty | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-organizational-unit | Swissnoso Organizational Unit | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-germ | Swissnoso Germ | active | 2022-06 | ch | hl7 | ||
hl7.fhir.us.eltss | R4 | ValueSet/eltss-observation-code | Observation Code Value Set | informative | hsswg | 2019-09 | us | hl7 | |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.11.20.9.69.6 | Planned or Completed moodCode | active | 2024-06 | us | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-bacterial-count-in-urine | Swissnoso Bacterial Count in Urine | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-clinical-symptom | Swissnoso Clinical Symptom | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-indication | Swissnoso Indication | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-number-of-different-germs | Swissnoso Number of Different Germs | active | 2022-06 | ch | hl7 | ||
ch.fhir.ig.swissnoso | R4 | ValueSet/swissnoso-procedure-location | Swissnoso Procedure Location | active | 2022-06 | ch | hl7 | ||
HIE2.packages | R4 | ValueSet/targetDiseases-uv-ips | Vaccine Target Diseases - IPS | active | 2022-01 | uv | hl7 | ||
ca.infoway.vc.ps | R4 | ValueSet/CVC-Generic | Canadian Vaccine Catalogue Vaccine Generic Names | draft | 2021-11 | ca | national | ||
ca.infoway.vc.ps | R4 | ValueSet/CVC-Tradename | Canadian Vaccine Catalogue Vaccine Tradenames | draft | 2021-11 | ca | national | ||
HIE2.packages | R4 | ValueSet/targetDiseases-gps-uv-ips | Vaccine Target Diseases (GPS) - IPS | active | 2022-01 | uv | hl7 | ||
HIE2.packages | R4 | ValueSet/vaccines-gps-uv-ips | Vaccines (GPS) - IPS | active | 2022-01 | uv | hl7 | ||
hl7.terminology | R5 | ValueSet/benefit-network | Network Type Codes | active | 1 | fm | 2025-05 | uv | hl7 |
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7664 | Data Elements (NND Babesiosis) | active | 2018-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7811 | Data Elements (CRS) | active | 2018-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7525 | Data Elements (NND CS) | active | 2018-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7663 | Data Elements (NND Malaria) | active | 2018-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7816 | Data Elements (Rubella) | active | 2018-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7665 | Data Elements (NND Varicella) | active | 2018-01 | us | |||
hl7.terminology | R5 | ValueSet/process-priority | Process Priority Codes | active | 1 | fm | 2024-04 | uv | hl7 |
hl7.terminology | R5 | ValueSet/consent-scope | Consent Scope Codes | active | 2 | cbcc | 2024-04 | uv | hl7 |
hl7.fhir.be.medication | R4 | ValueSet/BeMedicationLineRegistrationStatusVS | Medication Line Registration Status Value Set | draft | 2025-07 | be | hl7 | ||
ihe.pcc.maps | R4 | ValueSet/Antepartum.Family.History.and.Genetic.Screening.VS | Antepartum Family History and Genetic Screening | active | 2024-10 | uv | ihe | ||
hl7.fhir.us.pacio-toc | R4 | ValueSet/toc-loinc-answered-by-LL5571-6-vs | Transitions of Care LOINC Terms Answered by LL5571-6 Answer List Value Set | trial-use | 2 | pc | 2025-06 | us | hl7 |
hl7.fhir.us.pacio-toc | R4 | ValueSet/toc-del-loinc-vs | Transitions of Care DEL LOINC Terms Value Set | trial-use | 2 | pc | 2025-06 | us | hl7 |
hl7.fhir.us.pacio-toc | R4 | ValueSet/toc-del-loinc-answered-by-LL5571-6-vs | Transitions of Care LOINC Terms Included in the DEL Answered by LL5571-6 Answer List Value Set | trial-use | 2 | pc | 2025-06 | us | hl7 |
hl7.terminology | R5 | ValueSet/medical-management-type | Medical Management Type | active | 1 | fm | 2025-05 | uv | hl7 |
hl7.eu.fhir.idea4rc | R4 | ValueSet/disease-extent-category-vs | Sarcoma Staging: localized disease | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/locoregional-category-vs | Staging: loco-regional category | draft | 2025-07 | eu | hl7 | ||
hl7.fhir.uv.cqm | R4 | ValueSet/subject-type | Subject Type Value Set | trial-use | 4 | cqi | 2024-08 | uv | hl7 |
ca.on.oh.mha.pds | R4 | ValueSet/confirmed-diagnosis | Confirmed Diagnosis | draft | |||||
fi.digious.kanta.test | R4 | ValueSet/fiphr-vs-fitnessresult | Value Set Finnish PHR Fitness Results | active | 0 | 2018-12 | |||
fi.digious.kanta.test | R4 | ValueSet/fiphr-vs-vitalsigns | Value Set Finnish PHR Vital Signs | active | 2020-04 | ||||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.113883.11.20.9.38 | Current Smoking Status (NAACCR) | active | 2015-01 | us | |||
hl7.fhir.uv.ips | R4 | ValueSet/problem-type-loinc | Problem Type (LOINC) | trial-use | 2 | pc | 2025-08 | uv | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1099.28 | Problem Type (LOINC) | active | 2023-07 | us | hl7 | ||
ca.on.oh.mha.pds | R4 | ValueSet/opioid-agonist-medication | Opioid Agonist Medication | draft | ca | national | |||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.11.20.9.39 | Result Status | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1078.476 | Allergy To Vaccine Component | active | 2023-07 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1115.2 | InstructionActStatus | active | 2017-11 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.11.20.9.69.7 | Obligation or Prohibition Instruction Type | active | 2017-11 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.58 | Findings Related to Medication Management, Chronic Disease Present | active | 2023-12 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.59 | Findings Related to Medication Management, Taking Medication for Chronic Disease | active | 2017-08 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.150 | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.147 | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.144 | Bed Confinement Impairment | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.302 | Test Cervical Excision Procedures | active | 2023-10 | us | hl7 | ||
HIE2.packages | R4 | ValueSet/core-problem-finding-situation-event-gps-uv-ips | CORE Problem List Finding/Situation/Event (GPS) - IPS | active | 2022-01 | uv | hl7 | ||
hl7.fhir.uv.ebm | R6 | ValueSet/179431 | EvidenceReportSectionCode Value Set | active | 2025-08 | uv | hl7 | ||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7449 | Qualitative Lab Result (RCMT) | active | 2016-01 | us | |||
hl7.fhir.us.core | R4 | ValueSet/us-core-screening-assessment-observation-maximum-category | US Core Screening Assessment Observation Maximum Category | trial-use | 3 | cgp | 2024-11 | us | hl7 |
hl7.fhir.us.core | R4 | ValueSet/us-core-simple-observation-category | US Core Simple Observation Category | trial-use | 3 | cgp | 2024-11 | us | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.11.20.9.87 | Postpartum Status | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.190123 | Diagnostic Mammography Study | active | 2018-04 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1902 | Ultrasound of the Breast | active | 2019-01 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.190412 | Screening Mammography and DBT Studies | active | 2018-04 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4066 | Diagnostic DBT Study | active | 2022-05 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.13883.3.3157.4067 | MRI of the Breast | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.13883.3.3157.4068 | MRI of the Breast | active | 2022-05 | us | hl7 | ||
poc.bonsai.current | R4 | ValueSet/dispensing-restrictions | Utlämnandebegränsning | active | 2022-02 | ||||
poc.bonsai.current | R4 | ValueSet/narcotic-classification | Narkotikaklass | active | 2022-02 | ||||
poc.bonsai.current | R4 | ValueSet/product-types | Produkttyp | active | 2022-03 | ||||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1267.25 | Detailed race including absence reasons. | active | 2025-04 | us | hl7 | ||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.6066 | Ethnic Group (HL7) | active | 2012-01 | us | |||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1115.6 | Personal Health Goals LOINC | active | 2024-07 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1115.13 | Healthcare Agent Powers or Limitations Indicator | active | 2024-11 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1221.208 | Sexual Orientation | active | 2024-04 | us | hl7 | ||
ca.on.ehr.r4 | R4 | ValueSet/ValueSet-ErrorCode | Error Code EHR | active | 2025-01 | ca | national | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.264 | CDS Pregnancy | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.265 | CDS Pregnancy Intensional | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.11 | Cirrhosis ICD9CM | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.13 | Cirrhosis SNOMEDCT | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.14 | Cirrhosis | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1221.179 | Abortion Medications | active | 2024-04 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1221.184 | Letrozole (Aromatase inhibitor) | active | 2024-04 | us | hl7 | ||
hl7.fhir.uv.genomics-reporting | R4 | ValueSet/molecular-biomarker-category-vs | Molecular Biomarker Categories | informative | cg | 2025-06 | uv | hl7 | |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1260.12 | Negative | active | 2023-08 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1095.11 | Nutrition Focused Physical Findings SNOMED CT | active | 2025-01 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.207 | PharmacyEnvironmentsOfCare | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.205 | PharmacyTypeOfProfession | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.181 | PharmacyEncounterReason | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.197 | PharmacyAllergies | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.198 | PharmacyInterventions | active | 2024-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.200 | PharmacyReasonsForInterventions | active | 2024-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.201 | PharmacyInterventionStatus | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.202 | PharmacyCareCoordination | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.203 | PharmacyReferralsTo | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.204 | PharmacyGoalStatusOutcome | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.208 | PharmacyEncounterType | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.209 | PharmacytEncounterClass | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.211 | PharmacyAllergyIntoleranceType | active | 2018-09 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.212 | PharmacyAllergyIntoleranceManifestation | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.213 | PharmacyReasonForMedicationChange | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.214 | PharmacyEducation | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.215 | PharmacyEducationStatus | active | 2022-03 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1096.216 | PharmacyReferralsFrom | active | 2022-03 | us | hl7 | ||
hl7.eu.fhir.pcsp | R4 | ValueSet/mcode-cancer-stage-group-vs | Stage Group Value Set | draft | 2025-08 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-tnm-distant-metastases-category-clinical-vs | TNM Distant Metastases Category Value Set (Clinical) | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-tnm-distant-metastases-category-pathological-vs | TNM Distant Metastases Category Value Set (Pathological) | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.pcsp | R4 | ValueSet/mcode-tnm-distant-metastases-category-vs | TNM Distant Metastases Category Value Set | draft | 2025-08 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-tnm-regional-nodes-category-clinical-vs | TNM Regional Nodes Category Value Set (Clinical) | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-tnm-regional-nodes-category-pathological-vs | TNM Regional Nodes Category Value Set (Pathological) | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.pcsp | R4 | ValueSet/mcode-tnm-regional-nodes-category-vs | TNM Regional Nodes Category Value Set | draft | 2025-08 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-clinical-tnm-primary-tumor-category-vs | Clinical TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-pathological-tnm-primary-tumor-category-vs | Pathological TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.idea4rc | R4 | ValueSet/mcode-tnm-primary-tumor-category-vs | TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | hl7 | ||
hl7.eu.fhir.pcsp | R4 | ValueSet/mcode-tnm-primary-tumor-category-vs | TNM Primary Tumor Category Value Set | draft | 2025-08 | eu | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1115.7 | Health Goals Grouping | active | 2022-03 | us | hl7 | ||
hl7.terminology | R5 | ValueSet/reason-medication-given-codes | Reason Medication Given Codes | active | 1 | phx | 2024-04 | uv | hl7 |
hl7.fhir.uv.extensions | R5 | ValueSet/procedure-progress-status-codes | Procedure Progress Status Codes Value Set | trial-use | 3 | pc | 2025-08 | uv | hl7 |
hl7.fhir.uv.extensions | R5 | ValueSet/flag-priority | Flag Priority Codes Value Set | trial-use | 3 | pc | 2025-08 | uv | hl7 |
hl7.fhir.uv.order-catalog | R5 | ValueSet/laboratory-service-type | Types of diagnostic services performed by a laboratory | trial-use | 2 | oo | 2019-12 | uv | hl7 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1221.177 | Mifepristone | active | 2024-04 | us | hl7 | ||
hl7.fhir.uv.cow | R4 | ValueSet/business-status | Clinical Orders Workflow Business Status Codes | trial-use | 1 | oo | 2025-05 | uv | hl7 |
ihe.iti.scheduling | R4 | ValueSet/iti-sched-status-reason | IHE ITI Sched Status Reason Codes | active | 2018-03 | uv | ihe | ||
hl7.fhir.us.core | R4 | ValueSet/us-core-screening-assessment-observation-category | US Core Screening Assessment Observation Category | trial-use | 3 | cgp | 2024-11 | us | hl7 |
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7880 | Education (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7884 | Exposure Site Category (CO) | active | 2022-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7881 | Generator Location (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7876 | Intent of Exposure (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7882 | Generator Distance (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7878 | Exposure Source (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7888 | Signs and Symptoms (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7877 | Extreme Weather Type (CO) | active | 2022-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7891 | Data Reporting Source (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7887 | Underlying Conditions (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7883 | Person/Organization Taking CO Reading (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7886 | Treatment Location (CO) | active | 2019-01 | us | |||
us.cdc.phinvads | R4 | ValueSet/2.16.840.1.114222.4.11.7879 | Treatment Type (CO) | active | 2019-01 | us | |||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1248.107 | Mechanical Ventilation | active | 2022-05 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1248.109 | aPTT Tests | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1248.106 | Mechanical Ventilation | active | 2024-01 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1032.96 | Dependence on dialysis | active | 2024-06 | us | hl7 | ||
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1166.117 | Syphilis Tests | active | 2023-07 | us | hl7 |